Can you take Acid Controller Maximum Strength with Enzalutamide?
1 drug interaction and 9 additional warnings found for the following 2 drugs:
- Acid Controller Maximum Strength (famotidine)
- enzalutamide
Drug interactions
Moderate drug interactions
Moderate:
famotidine enzalutamide
Applies to: Acid Controller Maximum Strength (famotidine) and enzalutamide
Using famotidine together with enzalutamide can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Talk to your doctor if you have any questions or concerns.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Minor food/lifestyle interactions
Minor:
famotidine Nicotine
Applies to: Acid Controller Maximum Strength (famotidine)
Information for this minor interaction is available on the professional version.
Disease interactions
8 potential interactions Applies to: 7 conditions, including Seizures, Head Injury, Brain Tumor, Renal Dysfunction, and History - Cerebrovascular Disease.
Brain Tumor
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Brain Tumor.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
CNS Infection
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with CNS Infection.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Gastrointestinal Hemorrhage
Major:
Acid Controller Maximum Strength
The famotidine in Acid Controller Maximum Strength has a major potential interaction with Gastrointestinal Hemorrhage.
Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.
Head Injury
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Head Injury.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
History - Cerebrovascular Disease
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with History - Cerebrovascular Disease.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Renal Dysfunction
Moderate:
Acid Controller Maximum Strength
The famotidine in Acid Controller Maximum Strength has a moderate potential interaction with Renal Dysfunction.
Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous). The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients. Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients. Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient's clinical response.
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Renal Dysfunction.
Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.
Seizures
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Seizures.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Report options
More resources
Acid Controller Maximum Strength
A total of 331 drugs are known to interact with Acid Controller Maximum Strength.
- Acid controller maximum strength is in the drug class H2 antagonists.
- Acid controller maximum strength is used to treat the following conditions:
enzalutamide
A total of 703 drugs are known to interact with enzalutamide.
- Enzalutamide is in the following drug classes: antiandrogens, hormones/antineoplastics.
- Enzalutamide is used to treat Prostate Cancer.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.